JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
Semaglutide is a research compound studied in cell-based assay formats for its GLP-1R (class B GPCR) Gs/cAMP/PKA signalling with C18 fatty diacid albumin-binding modification. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.
Tirzepatide represents a dual incretin receptor agonist investigated through comprehensive in vitro pharmacological studies. Research demonstrates its simultaneous engagement of both GLP-1R and GIP receptor pathways, creating distinct signalling profiles compared to selective GLP-1R modulators. Laboratory investigations utilise transfected cell lines and primary cell cultures to elucidate the compound's receptor binding kinetics and downstream effector activation patterns.
Semaglutide acts via GLP-1R (class B GPCR) Gs/cAMP/PKA signalling with C18 fatty diacid albumin-binding modifications that extend its pharmacokinetic profile in research models. In vitro binding assays demonstrate high selectivity for GLP-1R with minimal cross-reactivity at related incretin receptors. Radioligand displacement studies reveal nanomolar binding affinity (Kd ~0.38 nM) in CHO-K1 cells expressing human GLP-1R.
The compound's structure incorporates specific amino acid substitutions at positions 8 and 34, along with the C18 fatty diacid chain attachment via lysine residue modification. These structural elements contribute to enhanced receptor binding stability and prolonged signalling duration observed in cyclic adenosine monophosphate (cAMP) accumulation assays.
Tirzepatide demonstrates dual agonist activity at both GLP-1R and glucose-dependent insulinotropic polypeptide receptor (GIPR) systems. In vitro pharmacological profiling reveals balanced potency across both receptor subtypes, with EC50 values of approximately 0.06 nM at GLP-1R and 0.24 nM at GIPR in transfected HEK293 cell lines.
The compound's molecular structure derives from GIP peptide backbone modifications, incorporating specific amino acid substitutions that maintain GIPR affinity while conferring GLP-1R activation capability. C20 fatty diacid chain conjugation provides albumin binding properties similar to semaglutide, enabling extended residence time in research model systems.
Both compounds activate Gs-coupled adenylyl cyclase pathways, though with distinct kinetic profiles. Time-course studies in pancreatic β-cell models demonstrate sustained cAMP elevation lasting 4-6 hours post-treatment with both peptides. However, tirzepatide exhibits enhanced peak cAMP responses attributed to its dual receptor engagement, particularly in cell lines co-expressing GLP-1R and GIPR.
Protein kinase A (PKA) phosphorylation assays reveal differential substrate targeting between the compounds. Semaglutide produces selective CREB phosphorylation patterns, while tirzepatide generates broader PKA substrate activation profiles reflecting its dual receptor mechanism.
Fluorescence resonance energy transfer (FRET) assays examining β-arrestin-2 recruitment patterns show distinct profiles for each compound. Semaglutide demonstrates prolonged β-arrestin association with GLP-1R, contributing to sustained receptor internalisation and signalling. Tirzepatide exhibits more rapid β-arrestin dissociation kinetics at both receptor subtypes, potentially influencing downstream pathway dynamics.
Saturation binding experiments utilising [125I]-GLP-1 as radiotracer demonstrate that semaglutide competes with nanomolar affinity at GLP-1R sites. Hill coefficients approaching unity suggest single-site binding interactions without cooperative effects. Tirzepatide shows similar GLP-1R binding affinity while additionally displacing [125I]-GIP at GIPR sites with comparable potency.
Concentration-response curves for cAMP accumulation reveal that both compounds achieve maximal efficacy relative to native peptide controls. Semaglutide demonstrates consistent EC50 values across multiple GLP-1R-expressing cell models (0.02-0.15 nM range), while tirzepatide shows receptor subtype-dependent potency variations reflecting its dual agonist profile.
Comparative in vitro pharmacological studies distinguish semaglutide as a selective GLP-1R agonist with high binding affinity and sustained signalling characteristics, while tirzepatide functions as a balanced dual incretin receptor agonist engaging both GLP-1R and GIPR pathways. Both compounds demonstrate nanomolar potency in cell-based assays, with structural modifications conferring albumin binding properties and extended pharmacokinetic profiles in research model systems. Their distinct receptor selectivity patterns and signalling kinetics provide valuable tools for investigating incretin pathway biology and comparative GPCR pharmacology mechanisms.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
